• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Myriad Genetics Inc (NQ: MYGN )

    27.09 -0.30 (-1.10%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 17, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 770,768
    Open 27.11
    Bid (Size) 24.74 (1)
    Ask (Size) 28.53 (1)
    Prev. Close 27.39
    Today's Range 26.96 - 27.57
    52wk Range 13.82 - 27.82
    Shares Outstanding 90,500,000
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
    New Nationwide Survey Findings Show That More Than Half of Women Do Not Know That Breast Density Can Reveal Increased Risk of Breast Cancer 
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
    From Myriad Genetics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +42.58%
    +42.58%
    1 Month
    +12.73%
    +12.73%
    3 Month
    +45.33%
    +45.33%
    6 Month
    +35.31%
    +35.31%
    1 Year
    +21.70%
    +21.70%

    More News

    Read More
    Key Takeaways From Myriad Genetics Analyst Ratings
    Via Benzinga
    Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    The 3 Best Gene Editing Stocks to Buy in July 2024
    Via InvestorPlace
    Myriad Genetics Earns 2024 Great Place To Work® Certification™
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests
    Via MarketBeat
    Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life
    Via InvestorPlace
    Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    MYGN Stock Earnings: Myriad Genetics Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.